SCHEMBL3244226

SCHEMBL3244226

COc1ccc(NS(=O)(=O)CN)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.65
CA2 P00918 4/20 0.65
GAA P10253 4/20 0.51
MAPK1 P28482 3/20 0.51
LMNA P02545 3/20 0.51
CA9 Q16790 3/20 0.49
CA12 O43570 2/20 0.49
CA4 P22748 1/20 0.49
CA7 P43166 1/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GFER P55789 1/20 0.48
PGR P06401 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
THRB P10828 1/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402087 0.86 CA1 (0.61) CA1CA2GAAMAPK1LMNA
SCHEMBL16691162 0.85 CA1 (0.63) CA1CA2GAAMAPK1LMNA
SCHEMBL3234157 0.80 LMNA (0.55) GAAMAPK1LMNAALDH1A1SMN1; SMN2
SCHEMBL2053820 0.79 PKM (0.58) CA1CA2GAAMAPK1LMNA
SCHEMBL10538487 0.79 CA1 (0.56) CA1CA2GAAMAPK1LMNA
SCHEMBL1645328 0.79 CA1 (1.00) CA1CA2GAAMAPK1LMNA
SCHEMBL11708669 0.78 CA1 (0.70) CA1CA2GAAMAPK1LMNA
SCHEMBL829810 0.77 CA1 (0.54) CA1CA2GAAMAPK1LMNA
SCHEMBL26618840 0.77 CA1 (0.54) CA1CA2GAAMAPK1LMNA
SCHEMBL3890273 0.77 CA1 (0.54) CA1CA2GAAMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
EP-1751097-B1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC (US) 2009-12-30 EP disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 US disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 CA1 4241/4885CA2 2477/4885GAA 53/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 CA1 4580/4885CA2 2403/4885GAA 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.